Full Text View
Tabular View
No Study Results Posted
Related Studies
Angiotensin II Antagonism of TGF-Beta 1
This study has been completed.
Study NCT00320970   Information provided by Providence Health & Services

First Received on April 28, 2006.   Last Updated on August 1, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diabetic Nephropathy
Hypertension
Additional conditions recognized in this trial
Diabetic Nephropathies
Kidney Diseases
More general conditions related to this trial
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Urologic Diseases
Vascular Diseases
Interventions listed in this trial
Candesartan
Additional drug interventions recognized in this trial
Angiotensin II
Candesartan cilexetil
More general drug interventions related to this trial
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Vasoconstrictor Agents
Sponsors listed in this trial
Providence Health & Services
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services